8-K: Kyverna's KYV-101 Shows Strong gMG Phase 2 Data

Kyverna Therapeutics announced positive interim Phase 2 data for KYV-101 in generalized myasthenia gravis, demonstrating robust efficacy and a manageable safety profile.

Summary

• Positive interim data from the Phase 2 portion of the KYSA-6 Phase 2/3 trial of KYV-101 in generalized myasthenia gravis (gMG) was announced.
• KYV-101 is a fully human autologous CD19 CAR T-cell therapy designed for potency and tolerability in autoimmune diseases.
• The study included 6 patients with moderate to severe gMG, aged 21-62 years, who had failed multiple prior immunosuppressive/immunomodulatory therapies.
• Patients received a single infusion of 1x10^8 CAR T cells after cyclophosphamide and fludarabine (Cy/Flu) lymphodepletion.
• The data cutoff for this interim analysis was October 3, 2025.

Sentiment

Score: 9

Explanation: The filing reports exceptionally strong positive interim Phase 2 clinical trial data for KYV-101 in gMG, demonstrating superior efficacy compared to existing and investigational treatments, coupled with a manageable safety profile. This significantly de-risks the Phase 3 trial and strengthens the company's commercial prospects.

Positives

• Robust, rapid, and sustained improvements in gMG symptoms were observed, regardless of prior biologic exposure.
• Significant mean reduction in Myasthenia Gravis Activities of Daily Living (MG-ADL) score of -8.0 at 24 weeks from a baseline of 11.2.
• Significant mean reduction in Quantitative Myasthenia Gravis (QMG) score of -7.7 at 24 weeks from a baseline of 17.3.
• 100% of patients achieved a clinically meaningful response by MG-ADL (3-point reduction) and QMG (3-point reduction).
• 67% of patients (2 out of 3 with 24 weeks follow-up) reached Minimal Symptom Expression (MSE), defined as an MG-ADL score of 0 or 1.
• 100% of patients were free of nonsteroidal immunosuppressants (NSISTs), high-dose steroids (>10mg), and FcRn and complement inhibitors up to 24 weeks.
• KYV-101 demonstrated a well-tolerated safety profile with no high-grade Cytokine Release Syndrome (CRS) and no Immune effector cell-Associated Neurotoxicity Syndrome (ICANS) observed.
• CRS was low-grade and manageable in all patients (Grade 1 in 4 patients, Grade 2 in 2 patients).
• Transient Grade 3/4 neutropenia occurred in 2 patients, which resolved within 10 days of infusion, was manageable with G-CSF, and not associated with infections.
• Robust CAR T-cell expansion and B-cell depletion were observed in all patients.
• Interim Phase 2 results increase confidence in Phase 3 power assumptions, efficient trial size, and co-primary endpoint measurement.
• Reductions in MG-ADL and QMG exceeded the magnitude of effect assumed for Phase 3 co-primary endpoints.

Risks

• The company's future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, and research and development costs are subject to risks and uncertainties.
• Plans for manufacturing, regulatory approvals, timing, and likelihood of success are uncertain and actual results could differ materially and adversely from anticipated or implied forward-looking statements.
• Results from named-patient basis access (IH) are not a substitute for, or intended to replace, clinical trials and may not be used as the basis for marketing approval by regulatory agencies.
• Comparisons of KYV-101's clinical outcomes to other approved or investigational therapies are derived from separate clinical settings and are not based on head-to-head studies.

Future Outlook

Kyverna Therapeutics is accelerating its potential first-in-class CAR T franchise with programs in generalized myasthenia gravis (gMG) and stiff person syndrome (SPS). The company has a clear path to a Biologics License Application (BLA) for gMG with an FDA-aligned Phase 3 trial, further de-risked by strong Phase 2 results. For SPS, the pivotal Phase 2 trial is fully enrolled, with topline data anticipated in 1H 2026 and a BLA filing targeted for 1H 2026. The company also plans to broaden access with a rapid whole-blood manufacturing process for KYV-102, targeting an IND filing in Q4 2025, and is strategically pursuing expansive opportunities in other autoimmune diseases like Multiple Sclerosis, Rheumatoid Arthritis, and Lupus Nephritis.

Management Comments

• Kyverna is uniquely positioned to fundamentally change the treatment paradigm in gMG.
• Data reinforces KYV-101's potential to deliver durable, drug-free, disease-free remission with a single dose.
• Kyverna is well positioned to deliver on a compelling commercial opportunity in gMG, a large and growing market.
• Today's unprecedented clinical trial results increase confidence in Kyverna's registrational Phase 3 superiority trial and path to BLA.

Industry Context

Generalized Myasthenia Gravis (gMG) is a B-cell and antibody-mediated neuromuscular autoimmune disease with a high disease burden despite available treatment options. Current treatments often result in inadequate symptom control, few patients reaching minimal symptom expression, and reliance on ongoing, costly immunosuppressant therapies. KYV-101, a CD19 CAR T-cell therapy, represents an upstream targeting approach at the disease source (B cells in lymphoid tissues), differentiating it from downstream therapies like complement inhibitors, FcRn inhibitors, and acetylcholinesterase inhibitors that transiently inhibit autoantibody activity or increase nerve signaling molecules. This positions KYV-101 as a potentially paradigm-shifting therapy offering single-dose treatment, unprecedented disease control, manageable safety, and the opportunity to remove background therapies.

Comparison to Industry Standards

• **MG-ADL Reduction**: KYV-101 (KYSA-6, n=3) achieved a mean reduction of 8.0, significantly higher than approved/investigational FcRn Inhibitor VYVGART (~4.6), Complement Inhibitor ULTOMIRIS (3.1), CD19 mAb UPLIZNA (4.2), and BCMA mRNA CAR T Descartes-08 (~4.2).
• **QMG Reduction**: KYV-101 (KYSA-6, n=3) achieved a mean reduction of 7.7, higher than VYVGART (~6.2), ULTOMIRIS (2.8), UPLIZNA (4.8), and Descartes-08 (~3.9).
• **% Responders (3-point MG-ADL improvement)**: KYV-101 achieved 100%, compared to VYVGART (~73%), ULTOMIRIS (~57%), UPLIZNA (~79%), and Descartes-08 (~70%).
• **Achieve Minimal Symptom Expression (MSE)**: KYV-101 achieved 67% (MG-ADL of 0 or 1), compared to VYVGART (40%), ULTOMIRIS (43%), and Descartes-08 (33%). UPLIZNA did not report this metric.
• These observations are derived from separate clinical settings; comparisons across trials are not based on head-to-head studies.

Stakeholder Impact

• **Shareholders**: Positive impact due to strong clinical data, de-risked Phase 3, and potential for a first-in-class therapy in a large market, increasing the likelihood of future revenue and market share.
• **Patients with gMG**: Significant positive impact as KYV-101 offers the potential for durable, drug-free, disease-free remission with a single dose, addressing the high unmet need for effective and less burdensome treatments.
• **Healthcare Providers**: Potential for a new, highly effective treatment option for gMG patients who have failed existing therapies.

Next Steps

• Initiate patient enrollment for the Phase 3 registrational trial for gMG by year-end 2025.
• Report topline pivotal Phase 2 data for Stiff Person Syndrome (SPS) in 1H 2026.
• File Biologics License Application (BLA) for SPS in 1H 2026.
• File KYV-102 Investigational New Drug (IND) Application in Q4 2025.
• Report Phase 1 data for Lupus Nephritis (LN) in a peer-reviewed publication in 2026.

Key Dates

Recommendation

The interim Phase 2 data for KYV-101 in gMG are exceptionally strong, demonstrating superior efficacy and a favorable safety profile compared to current and investigational treatments. The results significantly de-risk the upcoming Phase 3 trial and suggest a clear path to market for a potentially paradigm-shifting therapy in a large and underserved market. This positive clinical development, combined with a robust pipeline and strong cash position, indicates substantial upside potential for the stock.

Keywords

Kyverna Therapeutics, KYTX, Generalized Myasthenia Gravis, gMG, KYV-101, CAR T-cell therapy, Phase 2 trial, Clinical data, Autoimmune disease, Neuroimmunology, B-cell depletion, Minimal Symptom Expression, MG-ADL, QMG, Biologics License Application, FDA, Stiff Person Syndrome, SPS, Lupus Nephritis, LN, Multiple Sclerosis, MS, Rheumatoid Arthritis, RA